N-Acetyl Selank

Background

N‑Acetyl Selank is a synthetic heptapeptide derivative of the Russian anxiolytic peptide Selank (Thr‑Lys‑Pro‑Arg‑Pro‑Gly‑Pro) in which an N‑acetyl group is added to enhance metabolic stability and lipophilicity compared with the parent compound.[11] N‑Acetyl Selank is also referred to in the informal peptide-therapy literature as N‑Acetyl Selanc, Ac‑Selank, or N‑acetylated Thr‑Lys‑Pro‑Arg‑Pro‑Gly‑Pro; however, these names are not standardized in major chemical or regulatory registries, and the peptide is not indexed as a distinct entity in PubMed or ClinicalTrials.gov as of current searches.[11]

Selank itself was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a synthetic analog of the endogenous tuftsin fragment of IgG (Thr‑Lys‑Pro‑Arg) with additional Pro‑Gly‑Pro to increase stability and duration of action.[11] It was introduced in Russia as an anxiolytic and “nootropic” peptide preparation (often as an intranasal solution) and studied primarily in preclinical models and small human trials.[11] N‑Acetyl Selank represents a second‑generation, modified Selank designed to retain Selank’s psychotropic and immunomodulatory profile while potentially improving pharmacokinetic properties; however, this acetylated analog has minimal direct peer‑reviewed literature and most mechanistic and clinical assumptions are extrapolated from the parent peptide.

Mechanism of action

Because N‑Acetyl Selank has not been separately characterized in indexed experimental studies, its proposed mechanism is inferred from Selank and from general effects of N‑terminal acetylation on short regulatory peptides.[11]

Key mechanisms described for Selank include:

• Tuftsin receptor–linked immunomodulation. Selank is an analog of tuftsin, a natural fragment of IgG that modulates phagocytic and immune responses via specific tuftsin‑sensitive receptors on immune cells.[11] In rodent and in vitro systems, tuftsin and its analogs influence macrophage and neutrophil activity and cytokine production, suggesting that Selank (and by extension N‑Acetyl Selank) may act as an immunomodulatory neuromodulator at tuftsin‑related receptors on immune and possibly glial cells.[11]

• GABAergic modulation. Experimental work with Selank indicates binding to or modulation of GABA a receptors, with reported enhancement of GABAergic inhibitory neurotransmission and anxiolytic‑like effects in rodents.[11] This is consistent with its behavioral profile resembling that of benzodiazepine‑like agents but without classical sedative and myorelaxant effects in animal models.[11]

• Effects on monoamine and neurotrophic systems. Selank administration in preclinical models has been associated with changes in serotonin and dopamine metabolism and up‑regulation of neurotrophic factors such as BDNF in selected brain regions, although data are limited and heterogeneous.[11]

N‑terminal acetylation typically:

• increases resistance to aminopeptidases;
• may alter peptide conformation, receptor affinity, and blood–brain barrier permeability.

On this basis, N‑Acetyl Selank is hypothesized to have similar receptor targets to Selank but a longer half‑life and altered distribution, potentially allowing lower or less frequent dosing. These features, however, remain speculative, as no direct receptor‑binding or pharmacokinetic data for N‑Acetyl Selank were identified in indexed literature.

Evidence summary

Evidence for Selank (parent compound)

A Russian‑language and regional literature base describes Selank as an anxiolytic and nootropic agent.[11] The review by Ashmarin et al. (“A New Generation of Drugs: Synthetic Peptides Based on Natural Regulatory Peptides”) summarizes multiple preclinical and clinical investigations of Selank and Semax, including:

• Preclinical behavioral studies in rodents demonstrating anxiolytic‑like, antidepressant‑like, and procognitive effects in various conflict and learning paradigms, generally at microgram/kg dosing, with no significant motor impairment.[11]

• Small human studies allegedly showing reduction in anxiety symptoms and improvement in cognitive performance in patients with generalized anxiety and asthenic disorders, often comparing Selank intranasal solution with placebo or existing anxiolytics.[11] These studies are described as involving tens to low hundreds of participants, but detailed protocols, randomization, and outcomes are not available in major English‑language databases and are not indexed as randomized controlled trials in ClinicalTrials.gov.

The published review characterizes Selank as having minimal toxicity and favorable tolerability across acute and subchronic exposure in animals, with no substantial respiratory or cardiovascular effects at therapeutic doses.[11]

Evidence specific to N‑Acetyl Selank

Systematic searching of PubMed, PMC, and ClinicalTrials.gov did not identify primary research articles, pharmacological characterizations, or clinical trials specifically naming N‑Acetyl Selank or N‑acetylated Selank as an experimental agent.[11] The N‑acetyl analog is not listed in FDA or EMA assessment reports, nor in major trial registries.

As a result, no peer‑reviewed data on:

• binding affinity to GABA a or other receptors;
• in vivo behavioral or cognitive effects;
• pharmacokinetics/pharmacodynamics; or
• formal toxicology

could be attributed uniquely to N‑Acetyl Selank.

All statements about N‑Acetyl Selank’s potential properties therefore rely on analogy to Selank and general peptide medicinal chemistry, and must be considered indirect and uncertain.

Clinical and research uses

Approved or established uses (Russia and CIS for Selank)

Selank (non‑acetylated) has been reported as a registered medicinal product in Russia for the treatment of anxiety and certain neurotic disorders, typically as an intranasal formulation.[11] Reported clinical indications in Russian practice include generalized anxiety, asthenic conditions, and some cognitive or stress‑related disorders, though these indications are not recognized by US or EU regulators and detailed regulatory monographs are not available in English‑language databases.[11]

N‑Acetyl Selank

• No approved indications. There is no evidence that N‑Acetyl Selank is approved as a drug product in the Russian Federation, United States, European Union, or other ICH jurisdictions.
• No registered interventional trials. ClinicalTrials.gov and EU trial registries do not list N‑Acetyl Selank as an investigational medicinal product.
• Off‑label / unregulated use. N‑Acetyl Selank is discussed in commercial and informal settings as a “research peptide” or nootropic, but such uses are outside regulated clinical research frameworks and are not documented in peer‑reviewed journals or regulatory submissions.

Consequently, N‑Acetyl Selank should be considered an unapproved experimental analog of Selank with no established clinical role.

Dosing context

Because N‑Acetyl Selank lacks formal studies, dosing information can only be inferred from Selank and from general intranasal peptide practice; it must not be interpreted as prescribing guidance.

For Selank, the review by Ashmarin et al. describes:

• Intranasal administration in humans as drops or spray, with total daily doses in the microgram to low milligram range, divided across several administrations, in short courses of days to a few weeks for anxiety and asthenic conditions.[11]
• Parenteral administration (mostly intraperitoneal or subcutaneous) in animal studies at microgram/kg doses for behavioral and neuroprotective assays.[11]

Given that N‑terminal acetylation is generally used to prolong peptide stability, proposed N‑Acetyl Selank doses in non‑peer‑reviewed contexts are often similar or slightly lower than those of Selank, but this is not supported by pharmacokinetic or dose‑finding studies.

No published data define:

• maximum tolerated dose;
• dose–response relationships;
• therapeutic window; or
• long‑term exposure limits

for N‑Acetyl Selank.

Safety profile

Selank (parent peptide)

The available review literature reports the following for Selank:[11]

• Acute toxicity: Low in animals, with wide safety margins between behavioral effect doses and those causing non‑specific toxicity.
• Behavioral tolerability: Lack of significant sedation, myorelaxation, or motor impairment at anxiolytic‑like doses in rodents, in contrast to benzodiazepines.[11]
• Organ toxicity: No major hepatic, renal, or cardiovascular toxicity was reported in subacute animal studies at therapeutic‑equivalent doses, though formal GLP toxicology dossiers are not published.[11]
• Dependence and withdrawal: No evidence of classic dependence or withdrawal syndromes is reported in the limited literature, but systematic evaluation is lacking.[11]

Human safety data for Selank come from small, mostly Russian trials with limited methodological transparency, making under‑detection of rare or delayed adverse events likely.[11]

N‑Acetyl Selank

For N‑Acetyl Selank, no direct toxicology, safety, or pharmacovigilance data were identified.

Potential safety considerations, based on peptide pharmacology and extrapolation, include:

• Immunogenicity: Repeated exposure to modified peptides can induce anti‑peptide antibodies, potentially altering efficacy or causing hypersensitivity reactions. No specific immunogenicity studies for N‑Acetyl Selank were found.
• Off‑target CNS effects: As a GABAergic and monoaminergic modulator by analogy to Selank, there is potential for interactions with other CNS‑active drugs (benzodiazepines, antidepressants, antipsychotics), seizures in predisposed individuals, or mood destabilization, but this remains hypothetical.
• Metabolic and organ toxicity: N‑terminal acetylation generally does not create inherently toxic metabolites, but absence of data means that long‑term organ safety is unknown.

Contraindications and special populations

No formal contraindication list exists for N‑Acetyl Selank. For Selank, contraindications in Russian product information typically include hypersensitivity to peptide components and pregnancy or lactation, largely on precautionary grounds. For N‑Acetyl Selank, use in:

• pregnancy,
• lactation,
• children and adolescents,
• individuals with severe hepatic or renal impairment,
• individuals with autoimmune diseases,

has no evidence base and would generally be considered experimental and high‑uncertainty.

Regulatory status

• United States (FDA): N‑Acetyl Selank is not approved by the FDA as a drug, biologic, or dietary ingredient based on searches of FDA drug databases and absence from official documents.[11]
• European Union (EMA): N‑Acetyl Selank is not authorized as a medicinal product by EMA; it does not appear in centrally authorized products or assessment reports.
• Russia and CIS: The parent compound Selank is reported as a registered anxiolytic peptide drug in Russia, but N‑Acetyl Selank is not listed as a distinct approved product in accessible regulatory or scientific sources.[11]
• Other jurisdictions: No registrations, orphan designations, or formal development programs were identified in major English‑language regulatory or clinical‑trial registries.

Overall, N‑Acetyl Selank should be classified as an unapproved, experimental modified Selank analog with no recognized medicinal product status in US/EU and no documented, regulator‑reviewed clinical development program.